<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39444050</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2050-6511</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>23</Day></PubDate></JournalIssue><Title>BMC pharmacology &amp; toxicology</Title><ISOAbbreviation>BMC Pharmacol Toxicol</ISOAbbreviation></Journal><ArticleTitle>Bioequivalence study of eltrombopag 75 mg film-coated tablets under fasting conditions during the Covid-19 pandemic in healthy Caucasian male subjects.</ArticleTitle><Pagination><StartPage>80</StartPage><MedlinePgn>80</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">80</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40360-024-00803-0</ELocationID><Abstract><AbstractText>This study aims to determine the bioequivalence of the reference preparation and the test preparation containing eltrombopag when both were given during the COVID-19 pandemic while fasting. Participants in the research were healthy male Caucasian subjects. One film-coated tablet of the test preparation or one film tablet of the reference preparation, equivalent to 75 mg of eltrombopag, was given to the participants in a randomized order throughout each treatment session. At pre determined blood sampling points, blood samples were taken to determine the pharmacokinetics of eltrombopag. Eltrombopag concentrations in the samples were determined using an LC-MS/MS technique verified using ESI(-). The study results were used to calculate the rate (the maximum plasma concentration, or C<sub>max</sub>) and extent (area under the concentration-time curve of plasma, or AUC<sub>(0-72)</sub> and AUC<sub>(0-t)</sub> of eltrombopag absorption from the test preparation and reference preparation. The 90% confidence intervals (CI) of the ln-transformed AUC<sub>(0-72)</sub>, AUC<sub>(0-t)</sub>, and C<sub>max</sub> of eltrombopag met the bioequivalence requirements of 80.00-125.00%. Both trial preparations had a similar and very satisfactory safety profile.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Inal</LastName><ForeName>Ahmet</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Pharmacology, Hakan Cetinsaya Good Clinical Practise and Research Center, Erciyes University, Kayseri, Türkiye. ainal@erciyes.edu.tr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sezer</LastName><ForeName>Zafer</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Pharmacology, Hakan Cetinsaya Good Clinical Practise and Research Center, Erciyes University, Kayseri, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinarbasli</LastName><ForeName>Onur</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>ILKO Pharmaceuticals, Ankara, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bulut</LastName><ForeName>Burcu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>ILKO Pharmaceuticals, Ankara, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reinsch</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Analytisches Zentrum Biopharm GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Wolfgang</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Pharmakin Consulting Services UG, Neu-Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mazicioglu</LastName><ForeName>Mumtaz M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Department of Family Medicine, Hakan Cetinsaya Good Clinical Practise and Research Center, Erciyes University, Kayseri, Türkiye.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koru</LastName><ForeName>Selma Alime</ForeName><Initials>SA</Initials><AffiliationInfo><Affiliation>IDEAL Biyolojik Urunler ve Ilac Danismanlik Egitimi Ltd. Sti., Ankara, Türkiye.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000073843">Equivalence Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMC Pharmacol Toxicol</MedlineTA><NlmUniqueID>101590449</NlmUniqueID><ISSNLinking>2050-6511</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001565">Benzoates</NameOfSubstance></Chemical><Chemical><RegistryNumber>S56D65XJ9G</RegistryNumber><NameOfSubstance UI="C520809">eltrombopag</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006834">Hydrazines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013607">Tablets</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001565" MajorTopicYN="Y">Benzoates</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005215" MajorTopicYN="Y">Fasting</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064368" MajorTopicYN="N">Healthy Volunteers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006834" MajorTopicYN="Y">Hydrazines</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="Y">Pyrazoles</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013607" MajorTopicYN="Y">Tablets</DescriptorName><QualifierName UI="Q000493" MajorTopicYN="N">pharmacokinetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053719" MajorTopicYN="N">Tandem Mass Spectrometry</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013810" MajorTopicYN="Y">Therapeutic Equivalency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bioavailability</Keyword><Keyword MajorTopicYN="N">Bioequivalence study</Keyword><Keyword MajorTopicYN="N">Eltrombopag</Keyword><Keyword MajorTopicYN="N">Pharmacokinetic</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>0</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39444050</ArticleId><ArticleId IdType="doi">10.1186/s40360-024-00803-0</ArticleId><ArticleId IdType="pii">10.1186/s40360-024-00803-0</ArticleId><ArticleId IdType="pmc">PMC11515640</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Giai V, Poloni A. Eltrombopag for low-risk myelodysplastic syndromes with thrombocytopenia: ınterim results of a phase II, randomized, placebo-controlled clinical trial (EQOL-MDS). J Clin Oncol. 2023;41(28):4486–96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10552995</ArticleId><ArticleId IdType="pubmed">37294914</ArticleId></ArticleIdList></Reference><Reference><Citation>Revolade International non-proprietary name: eltrombopag/eltrombopag olamine 17 December 2015 EMA/CHMP/38474/2016. https://www.ema.europa.eu/en/documents/variation-report/revolade-h-c-1110-ii-0023-epar-assessment-report-variation_en.pdf. Accessed 25 July 2024.</Citation></Reference><Reference><Citation>PROMACTA-eltrombopag olamine tablet, film coated highlights of prescribing information. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7714a0ed-34bb-46e6-a0a5-b363908b22c2%26version=21. Accessed 25 July 2024.</Citation></Reference><Reference><Citation>Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs. 2008;68(7):901–12.</Citation><ArticleIdList><ArticleId IdType="pubmed">18457458</ArticleId></ArticleIdList></Reference><Reference><Citation>PROMACTA® (eltrombopag) tablets, for oral use highlights of prescribing information. https://www.novartis.com/us-en/sites/novartis_us/files/promacta.pdf. Accessed 25 July 2024.</Citation></Reference><Reference><Citation>Williams DD, Peng B, Bailey CK, Wire MB, Deng Y, Park JW, Collins DA, Kapsi SG, Jenkins JM. Effects of food and antacids on the pharmacokinetics of eltrombopag in healthy adult subjects: two single-dose, open-label, randomized-sequence, crossover studies. Clin Ther. 2009;31(4):764–76.</Citation><ArticleIdList><ArticleId IdType="pubmed">19446149</ArticleId></ArticleIdList></Reference><Reference><Citation>Alvaiz Generic Name: eltrombopag tablets. https://www.rxlist.com/alvaiz-drug.htm. Accessed 25 July 2024.</Citation></Reference><Reference><Citation>Burness CB, Gillian MK, Garnock-Jones KP. Eltrombopag: a review in Paediatric Chronic Immune Thrombocytopenia. Drugs. 2016;76:869–78.</Citation><ArticleIdList><ArticleId IdType="pubmed">27151255</ArticleId></ArticleIdList></Reference><Reference><Citation>Sözer G, Inal A, Sezer Z, Martin W, Ottmann E, Reinsch M, Koru SA. Bioequivalence study of capsules versus film tablets containing rivaroxaban in healthy Caucasian subjects under fasting and fed conditions. Clin Pharmacologyin Drug Dev. 2024;13(3):281–7.</Citation></Reference><Reference><Citation>Inal A, Sezer Z, Uluözlü B, Oflas M, Reinsch M, Martin W, Mazicioglu MM, Koru SA. Bioequivalence study of low dose drospirenone/ethinyl estradiol 3 mg/0.03 mg film tablets under fasting conditions in Turkish healthy female subjects. Pharmacol Res Perspect. 2024;12(4):e1253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11266778</ArticleId><ArticleId IdType="pubmed">39044631</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmaceutical and medical preparations law; No: 1262. Publication date in the official gazette: 26th May, 1928 Issue No. 898. https://titck.gov.tr/storage/legislation/meFOxeFD.pdf</Citation></Reference><Reference><Citation>GCP regulations. Turkish pharmaceuticals and medical devices agency, 13 Nov 2015. https://titck.gov.tr/storage/Archive/2020/legislation/KADKLVZ01IKU13.11.2015Rev08_13ac0133-274b-44dc-98cd-33998758cc72.pdf.</Citation></Reference><Reference><Citation>Guideline on the investigation of bioequivalence Committee for Medicinal Products for Human Use (CHMP) CPMP/EWP/QWP/1401/98 Rev. 1/Corr**, London, 20 Jan 2010. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-bioequivalence-rev1_en.pdf. Accessed 25 July 2024.</Citation></Reference><Reference><Citation>Guideline on bioanalytical method validation EMEA/CHMP/EWP/192217/2009. 21 July 2011. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-bioanalytical-methodvalidation_en.pdf. Accessed 25 July 2024.</Citation></Reference><Reference><Citation>Guidance for Industry Bioanalytical Method Validation U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Veterinary Medicine (CVM). May 2018. https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf. Accessed 28 July 2024.</Citation></Reference><Reference><Citation>Grabowski T, Marczak M, Jaroszewski JJ, Whitmire M. Comparison of bioequivalence study regulatory requirements for human and veterinary drugs. Regul Toxicol Pharmacol. 2012;64:233–42.</Citation><ArticleIdList><ArticleId IdType="pubmed">22917973</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>